10 min read · April 7, 2026
How to read a psychedelic clinical trial without getting fooled.
A working operator's guide to the eight things that matter in a Phase 2 readout, and the four that almost always get overhyped. Bring a pen.
8 min read · March 15, 2026
The 2026 regulatory map for psychedelic medicine.
FDA, MHRA, Health Canada, EMA, plus the state-by-state picture in the US. Where things actually stand right now, with primary citations.
12 min read · February 20, 2026
What separates a credible life sciences company from the rest.
After 11 years building operations in cannabis and psychedelics, here are the seven signals investors and patients can use to tell the difference.